Government-Owned Inventions; Availability for Licensing, 11364 [2017-03451]
Download as PDF
<![CDATA[
11364
Federal Register / Vol. 82, No. 34 / Wednesday, February 22, 2017 / Notices
Time: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Ramesh Vemuri, Ph.D.,
Chief, Scientific Review Branch, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, 7201 Wisconsin
Avenue, Suite 2C–212, Bethesda, MD 20892,
301–402–7700, rv23r@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: February 16, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03446 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
Inhibition of host heme oxygenase-1
as an adjunctive treatment to improve
the outcome of conventional antibiotic
chemotherapy of Mycobacterium
tuberculosis (Mtb) infection.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
Description of Technology
This invention describes the
adjunctive use of heme oxygenase-1
VerDate Sep<11>2014
16:05 Feb 21, 2017
Jkt 241001
(HO–1) inhibitors to improve the
outcome of conventional antibiotic
treatment for tuberculosis. The existent
standard of care requires prolonged
administration of drug. Due to the long
duration of treatment, methods that can
more rapidly control tuberculosis in
patients are clearly needed.
NIAID researchers have discovered
that inhibition of host HO–1 reduces
Mycobacterium tuberculosis (Mtb)
growth in vivo and, more importantly,
when used as an adjunct to
conventional chemotherapy, results in a
marked improvement in pulmonary
bacterial control. In particular, it was
found using a mouse model that HO–1
inhibitors enhance bacterial clearance
when used in conjunction with
conventional antibiotic therapy.
Further, no obvious toxic side effects
were found. Since this host-directed
strategy does not directly target the
pathogen itself, it may have an added
advantage as a treatment for infections
with antibiotic-resistant Mtb strains.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutic for Mtb.
Competitive Advantages:
• Innovative, more rapidly effective
therapeutics for tuberculosis are sorely
needed due to the continued importance
of TB as a global infectious disease and
the increasing emergence of multi-drug
resistant strains.
• This invention is a host-directed
therapy.
Development Stage: Pre-Clinical.
Inventors:
F. Alan Sher, NIAID, NIH
Diego L. Costa, NIAID, NIH
Bruno B. Andrade, NIAID, NIH
Publications: Costa, Diego L., et al.
‘‘Pharmacological Inhibition of Host
Heme Oxygenase-1 Suppresses
Mycobacterium tuberculosis Infection In
Vivo by a Mechanism Dependent on T
Lymphocytes.’’ mBio 7.5 (2016):
e01675–16.
Intellectual Property: HHS Reference
No. E–174–2016/0—U.S. Patent
Application No. 62/357,558, filed 07/
01/2016.
Licensing Contact: James M.
Robinson; James.Robinson4@nih.gov;
301–761–7542.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further evaluate HO–1 inhibitors in
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
treating human tuberculosis. For
collaboration opportunities, please
contact James M. Robinson;
James.Robinson4@nih.gov; 301–761–
7542.
Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03451 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Radiotherapy in Combination with Systemic
Agents.
Date: March 20, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W234, Bethesda, MD 20892–9750,
240–276–6368, Stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Questions 12.
Date: March 23, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
E:\FR\FM\22FEN1.SGM
22FEN1
]]>Agencies
[Federal Register Volume 82, Number 34 (Wednesday, February 22, 2017)]
[Notices]
[Page 11364]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03451]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by communicating
with the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Inhibition of host heme oxygenase-1 as an adjunctive treatment to
improve the outcome of conventional antibiotic chemotherapy of
Mycobacterium tuberculosis (Mtb) infection.
Description of Technology
This invention describes the adjunctive use of heme oxygenase-1
(HO-1) inhibitors to improve the outcome of conventional antibiotic
treatment for tuberculosis. The existent standard of care requires
prolonged administration of drug. Due to the long duration of
treatment, methods that can more rapidly control tuberculosis in
patients are clearly needed.
NIAID researchers have discovered that inhibition of host HO-1
reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more
importantly, when used as an adjunct to conventional chemotherapy,
results in a marked improvement in pulmonary bacterial control. In
particular, it was found using a mouse model that HO-1 inhibitors
enhance bacterial clearance when used in conjunction with conventional
antibiotic therapy. Further, no obvious toxic side effects were found.
Since this host-directed strategy does not directly target the pathogen
itself, it may have an added advantage as a treatment for infections
with antibiotic-resistant Mtb strains.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Therapeutic for Mtb.
Competitive Advantages:
Innovative, more rapidly effective therapeutics for
tuberculosis are sorely needed due to the continued importance of TB as
a global infectious disease and the increasing emergence of multi-drug
resistant strains.
This invention is a host-directed therapy.
Development Stage: Pre-Clinical.
Inventors:
F. Alan Sher, NIAID, NIH
Diego L. Costa, NIAID, NIH
Bruno B. Andrade, NIAID, NIH
Publications: Costa, Diego L., et al. ``Pharmacological Inhibition
of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis
Infection In Vivo by a Mechanism Dependent on T Lymphocytes.'' mBio 7.5
(2016): e01675-16.
Intellectual Property: HHS Reference No. E-174-2016/0--U.S. Patent
Application No. 62/357,558, filed 07/01/2016.
Licensing Contact: James M. Robinson; James.Robinson4@nih.gov; 301-
761-7542.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
evaluate HO-1 inhibitors in treating human tuberculosis. For
collaboration opportunities, please contact James M. Robinson;
James.Robinson4@nih.gov; 301-761-7542.
Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03451 Filed 2-21-17; 8:45 am]
BILLING CODE 4140-01-P
